These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

718 related articles for article (PubMed ID: 14697898)

  • 61. The presence of the type A form of monoamine oxidase within nigrostriatal dopamine-containing neurons.
    Demarest KT; Smith DJ; Azzaro AJ
    J Pharmacol Exp Ther; 1980 Nov; 215(2):461-8. PubMed ID: 7441510
    [TBL] [Abstract][Full Text] [Related]  

  • 62. (-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain.
    Knoll J
    Pharmacol Toxicol; 1998 Feb; 82(2):57-66. PubMed ID: 9498233
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The influence of metabolism on the MAO-B inhibitory potency of selegiline.
    Haberle D; Szökõ E; Magyar K
    Curr Med Chem; 2002 Jan; 9(1):47-51. PubMed ID: 11860347
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Antiapoptotic effect of (-)-deprenyl in rat kidney after ischemia-reperfusion.
    Toronyi E; Hamar J; Magyar K; Szende B
    Med Sci Monit; 2002 Feb; 8(2):BR65-8. PubMed ID: 11859269
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Attenuation of 1-methyl-4-phenylpyridinium (MPP+) neurotoxicity by deprenyl in organotypic canine substantia nigra cultures.
    Schmidt DE; Ebert MH; Lynn JC; Whetsell WO
    J Neural Transm (Vienna); 1997; 104(8-9):875-85. PubMed ID: 9451719
    [TBL] [Abstract][Full Text] [Related]  

  • 66. L-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats.
    Saravanan KS; Sindhu KM; Senthilkumar KS; Mohanakumar KP
    Neurochem Int; 2006 Jul; 49(1):28-40. PubMed ID: 16490285
    [TBL] [Abstract][Full Text] [Related]  

  • 67. (-)Deprenyl in perspective: prophylaxis for Parkinson's disease?
    Sandler M
    J Neural Transm Suppl; 1986; 22():107-15. PubMed ID: 3097254
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Type B and A monoamine oxidase and their inhibitors regulate the gene expression of Bcl-2 and neurotrophic factors in human glioblastoma U118MG cells: different signal pathways for neuroprotection by selegiline and rasagiline.
    Inaba-Hasegawa K; Shamoto-Nagai M; Maruyama W; Naoi M
    J Neural Transm (Vienna); 2017 Sep; 124(9):1055-1066. PubMed ID: 28577058
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Effect of solubilization by methylethylketone of rat liver mitochondrial monoamine oxidase on inhibition by clorgyline and deprenyl of the enzyme activity].
    Severina IS; Klimova GI; Nersisian AA
    Biokhimiia; 1981 Nov; 46(11):2043-55. PubMed ID: 6797482
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
    Fernandez HH; Chen JJ
    Pharmacotherapy; 2007 Dec; 27(12 Pt 2):174S-185S. PubMed ID: 18041937
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Deprenyl in Parkinson's disease: mechanisms, neuroprotective effect, indications and adverse effects.
    Vezina P; Mohr E; Grimes D
    Can J Neurol Sci; 1992 Feb; 19(1 Suppl):142-6. PubMed ID: 1571860
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Metabolic transformation plays a primary role in the psychostimulant-like discriminative-stimulus effects of selegiline [(R)-(-)-deprenyl].
    Yasar S; Justinova Z; Lee SH; Stefanski R; Goldberg SR; Tanda G
    J Pharmacol Exp Ther; 2006 Apr; 317(1):387-94. PubMed ID: 16352699
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The neuroprotective and neuronal rescue effects of (-)-deprenyl.
    Magyar K; Szende B; Lengyel J; Tarczali J; Szatmáry I
    J Neural Transm Suppl; 1998; 52():109-23. PubMed ID: 9564614
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Inhibition of the bioactivation of the neurotoxin MPTP by antioxidants, redox agents and monoamine oxidase inhibitors.
    Herraiz T; Guillén H
    Food Chem Toxicol; 2011 Aug; 49(8):1773-81. PubMed ID: 21554916
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Anti-apoptotic and apoptotic action of (-)-deprenyl and its metabolites.
    Szende B; Bökönyi G; Bocsi J; Kéri G; Timár F; Magyar K
    J Neural Transm (Vienna); 2001; 108(1):25-33. PubMed ID: 11261744
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease.
    Weinstock M; Gorodetsky E; Poltyrev T; Gross A; Sagi Y; Youdim M
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Jun; 27(4):555-61. PubMed ID: 12787840
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Improvement of mouse brain mitochondrial function after deprenyl treatment.
    Czerniczyniec A; Bustamante J; Lores-Arnaiz S
    Neuroscience; 2007 Jan; 144(2):685-93. PubMed ID: 17084986
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms.
    Naoi M; Maruyama W; Inaba-Hasegawa K
    Expert Rev Neurother; 2013 Jun; 13(6):671-84. PubMed ID: 23739004
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pharmacokinetic aspects of deprenyl effects.
    Magyar K; Tóthfalusi L
    Pol J Pharmacol Pharm; 1984; 36(4):373-84. PubMed ID: 6441926
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
    Henchcliffe C; Schumacher HC; Burgut FT
    Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.